Molnupiravir and Drug Development at Emory

Emory University has discovered and advanced the development of some of the world’s most important and valuable antiviral drugs, successfully taking treatments from bench to bedside. 

As one of the nation’s leading research universities, a key mission for Emory is to improve lives and provide hope to everyone we serve in all facets of our work. The criteria by which we measure our success include but are not limited to the lives saved, partnerships forged, solutions provided to real-world issues, and the scientific discoveries and foundation developed that will improve the health, wellness and safety of individuals around the globe for generations to come.

About Molnupiravir 

Drug Innovation Ventures at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University, invented EIDD-2801, which is now Molnupiravir. The drug targets the viral polymerase, an enzyme needed for the virus to make copies of itself. The oral antiviral is designed to work by introducing errors into the genetic code of the virus. 

Molnupiravir is currently being developed by Merck & Co. Inc. in collaboration with Ridgeback Biotherapeutics, which licensed the drug from DRIVE in 2020. It could be the first oral antiviral medicine to treat COVID-19.  

On October 11, Merck and Ridgeback announced submission of EUA application to FDA for Molnupiravir.

For more information, visit the Drug Discovery at Emory website.

Media Contact

Gana Ahn
404-727-0343
gana.ahn@emory.edu


Featured Stories »

A photo of molnupiravir pills

United Kingdom becomes first country to approve Emory-discovered drug for COVID-19

An Emory-invented antiviral treatment for COVID-19 has been authorized by British regulators, making molnupiravir the first antiviral pill approved for use against SARS-CoV-2. An emergency use application is also under consideration by the U.S. Food and Drug Administration.

Two red pills overlap each other on a white surface

Emory supports Medicines Patent Pool and Merck license agreement for molnupiravir to treat COVID-19

The Medicines Patent Pool and Merck have entered into a licensing agreement to facilitate affordable access for molnupiravir, an investigational oral antiviral COVID-19 medicine, in 105 low- and middle-income countries.

Emory president discusses research excellence and molnupiravir discovery

With Merck’s findings that Emory-discovered molnupiravir may significantly reduce the risk of hospitalization or death from COVID-19, Emory President Gregory L. Fenves joins epidemiologist Jodie Guest in a conversation about Emory’s history of research innovation.

A photo of Molnupiravir pills

EUA application submitted for COVID-19 antiviral discovered at Emory

Molnupiravir, an investigational oral antiviral drug discovered by Emory researchers, appears to significantly reduce the risk of hospitalization or death in patients with mild to moderate COVID-19, according to interim data from a Phase 3 study.

An artistic rendering of COVID-19 in lungs

A new antiviral drug heading into clinical trials offers hope for COVID-19 treatment — in part because it can be taken as a pill

Scientists are hopeful that a new drug discovered by researchers at Emory could change the way doctors treat COVID-19. The drug, called EIDD-2801, shows promise in reducing lung damage and has finished testing in mice. It will soon move to human clinical trials.

An artist's rendering of a mask over a globe

Drug launched at Emory reduces virus that causes COVID-19 to undetectable levels

An antiviral drug initially discovered by Emory’s non-profit drug development company DRIVE appears safe and reduces SARS-CoV-2 to undetectable levels in COVID-19 patients after five days of administration, according to data from a Phase II clinical trial.

Molecular picture of how antiviral drug molnupiravir works

Scientists at the Max Planck Institute for Biophysical Chemistry in Germany have generated a structure showing how the antiviral drug molnupiravir drug works.

George Painter

Antiviral drug invented by Emory’s DRIVE licensed in India for COVID-19 emergency

To address the intensifying COVID-19 crisis in India, the pharmaceutical company Merck has agreed to facilitate the manufacture and distribution of molnupiravir, an investigational antiviral drug that was discovered at Emory.

George Painter

Faculty Profile: Dr. George Painter

George Painter is a professor in the Department of Pharmacology and Chemical Biology at the Emory University School of Medicine, director of the Emory Institute for Drug Development and CEO of Drug Innovation Ventures at Emory (DRIVE).

More News »

AJC: Opinion: Public engagement: The next scientific revolution

Nov. 23, 2021

CNN: The FDA will soon decide on Merck's Covid-19 antiviral pill. It shows promise, but there are also concerns

Nov. 23, 2021

Wall Street Journal: Merck COVID-19 pill cleared for use in UK, its first authorization

Nov. 4, 2021

Washington Post: Britain authorizes Merck’s molnupiravir, the world’s first approval of oral covid-19 treatment pill

Nov. 4, 2021

Associated Press: UK authorizes Merck antiviral pill, 1st shown to treat COVID

Nov. 4, 2021

United Kingdom becomes first country to approve Emory-discovered drug for COVID-19

Nov. 4, 2021

BioSpace: Merck’s molnupiravir: When a private-public partnership bears fruit

Nov. 3, 2021

Emory supports Medicines Patent Pool and Merck license agreement for molnupiravir to treat COVID-19

Oct. 27, 2021

Emory president discusses research excellence and molnupiravir discovery

Oct. 18, 2021

USA TODAY: Drugmakers seek FDA emergency authorization for molnupiravir, antiviral pill to treat COVID-19: Latest updates

Oct. 11, 2021

Nature: How antiviral pill molnupiravir shot ahead in the COVID drug hunt

Oct. 8, 2021

Wall Street Journal: Pill intended to be COVID-19’s Tamiflu succeeds in key study

Oct. 1, 2021

USA TODAY: New antiviral is highly effective, study finds, and is stirring hope that COVID-19 could be treated by a pill

Oct. 1, 2021

ABC News: New COVID-19 pills may keep recently diagnosed patients out of hospital, company says

Oct. 1, 2021

Bloomberg: Merck’s COVID pill changes drugmaker’s fate after failed shots

Oct. 1, 2021

STAT: Merck’s antiviral pill reduces hospitalization of Covid patients, a possible game-changer for treatment

Oct. 1, 2021

BioPharma Dive: Merck says antiviral pill effective against COVID-19, lifting hopes for first oral drug

Oct. 1, 2021

Chemistry World: Where are the COVID-19 drugs?

Oct. 1, 2021

Contagion Live: Molnupiravir could become the first authorized COVID-19 pill

Oct. 1, 2021

Daily Mail: Merck says its experimental COVID-19 pill cut hospitalizations and deaths by HALF in people recently infected with the virus - and plans to apply for FDA approval

Oct. 1, 2021

CNN: A pill to treat Covid-19: 'We're talking about a return to, maybe, normal life'

Oct. 1, 2021

NPR: Merck to seek emergency authorization for pill it says cuts COVID-19 effects

Oct. 1, 2021

GPB: Promising COVID pill cuts hospitalizations and death in half. Atlanta's Emory University invented it

Oct. 1, 2021

Gizmodo: Merck and Ridgeback say their COVID-19 pill cuts chance of hospitalization and death by half

Oct. 1, 2021

WXIA/11Alive: First pill to treat COVID, now headed for approval process, was discovered by Emory researchers

Oct. 1, 2021

The Scientist: Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial

Oct. 1, 2021

AJC: Emory University research helps develop potential COVID-19 treatment drug

Oct. 1, 2021

EUA application submitted for COVID-19 antiviral discovered at Emory

Oct. 1, 2021

ScienceDirect: Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19

Oct. 1, 2021

Kaiser Health News: A daily pill to treat COVID could be just months away, scientists say

Sep. 24, 2021

New York Times: The U.S. will spend $3 billion on developing antiviral pills to treat Covid-19

June 17, 2021

medRxiv: Molnupiravir, an oral antiviral treatment for COVID-19

June 17, 2021

Business Wire: Merck announces supply agreement with U.S. government for molnupiravir, an investigational oral antiviral candidate for treatment of mild to moderate COVID-19

June 9, 2021

PBS News Hour: Scientists hope they’re closing in on a cure for COVID-19

June 1, 2021

The Economic Times: Seeking a pill to cure Covid: drugmakers eye alternative to vaccines

May 27, 2021

Global Atlanta: Merck to license Emory antiviral drug to combat India’s COVID-19 surge

May 3, 2021

MedPage Today: How molnupiravir moved to the head of the 'COVID pill' pack

April 28, 2021

Antiviral drug invented by Emory’s DRIVE licensed in India for COVID-19 emergency

April 27, 2021

Bloomberg Businessweek: Merck’s little brown pill could transform the fight against COVID

Mar. 25, 2021

Drug launched at Emory reduces virus that causes COVID-19 to undetectable levels

March 17, 2021

Nature: SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801

Feb. 9, 2021

Chemical and Engineering News: Emory-discovered antiviral is poised for COVID-19 clinical trials

Mar. 26, 2020